MedTrace Logo

Quality of Life in Diarrhea-predominant Irritable Bowel Syndrome Taking GABA

NCT06755489 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-02-05

No results posted yet for this study

Summary

The study aims to evaluate the impact on quality of life and abdominal discomfort of GABA and Melissa food supplement administration in patients with diarrhea-predominant irritable bowel syndrome.

Conditions

  • Diarrhoea Predominant Irritable Bowel Syndrome

Interventions

OTHER

Placebo

530 mg tablets containing microcrystalline cellulose, rice bran, bitter cocoa powder table 530 mg. 1 tablet three times a day

OTHER

GABA

530 mg tablets containing Gamma-aminobutyric acid (GABA) and different bulking agent as microcrystalline cellulose, calcium carbonate, lemon balm d.e. Leaves (melissa officinalis l. - maltodextrin) tit. 2% in rosmarinic acid, anti-caking agents: silicon dioxide, vegetable magnesium stearate. 1 tablet three times a day

Sponsors & Collaborators

  • Azienda Ospedaliero-Universitaria Pisana (AOUP)

    collaborator UNKNOWN

  • University of Pisa

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-17
Primary Completion
2024-11-19
Completion
2025-03-21

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06755489 on ClinicalTrials.gov